Cargando…

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

BACKGROUND: To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (MRI) scores, human leukocyte antigen (HLA)-B27 status, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braun, Jürgen, Blanco, Ricardo, Marzo-Ortega, Helena, Gensler, Lianne S., van den Bosch, Filip, Hall, Stephen, Kameda, Hideto, Poddubnyy, Denis, van de Sande, Marleen, Wiksten, Anna S., Porter, Brian O., Shete, Abhijit, Richards, Hanno B., Haemmerle, Sibylle, Deodhar, Atul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418044/ https://www.ncbi.nlm.nih.gov/pubmed/34481517 http://dx.doi.org/10.1186/s13075-021-02613-9

Ejemplares similares

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
por: Deodhar, Atul, et al.
Publicado: (2019)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
por: Tahir, Hasan, et al.
Publicado: (2017)

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial
por: Poddubnyy, Denis, et al.
Publicado: (2021)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2022)

Effect of Biologics in Subgroups of Axial Spondyloarthritis Based on Magnetic Resonance Imaging and C‐Reactive Protein: A Systematic Review and Meta‐Analysis
por: Karmacharya, Paras, et al.
Publicado: (2023)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
por: Braun, Jürgen, et al.
Publicado: (2021)

Old and new treatment targets in axial spondyloarthritis
por: Rios Rodriguez, Valeria, et al.
Publicado: (2015)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Treatment of Axial Spondyloarthritis: What Does the Future Hold?
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis
por: Poddubnyy, Denis
Publicado: (2020)

Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020)

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
por: Sun, Yuankai, et al.
Publicado: (2022)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

What is the optimal target for a T2T approach in axial spondyloarthritis?
por: Sieper, Joachim, et al.
Publicado: (2021)

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
por: Maksymowych, Walter P, et al.
Publicado: (2022)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
por: van Boheemen, Laurette, et al.
Publicado: (2020)

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
por: Aparicio, María, et al.
Publicado: (2021)

Patient‐reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID‐19 Pandemic
por: Liew, Jean W., et al.
Publicado: (2020)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis
por: Liew, Jean W, et al.
Publicado: (2020)

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
por: Ramonda, Roberta, et al.
Publicado: (2022)

Choose wisely: imaging for diagnosis of axial spondyloarthritis
por: Diekhoff, Torsten, et al.
Publicado: (2022)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
por: Smolen, Josef S, et al.
Publicado: (2018)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Defining the target: clinical aims in axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2018)

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
por: de Winter, Janneke J., et al.
Publicado: (2018)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ucpvv95jmsgu23vrifvvfqqnp4